| | Scope | Document part | Language | Document |
|---|
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 4 Absatz 23 | HM | § 4
Absatz 23 | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40 | G | § 40 | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40a | G | § 40a | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b Absatz 5 | HM | § 40b
Absatz 5 | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40b-001 | G | § 40b | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 41 | HM | § 41 | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 41a | G | § 41a | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 42c | HM | § 42c | DE | DEU AMG - Arzneimittelgesetz 19-Jul-2023 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 11 | G | Article 11 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 2 Paragraph 2 No. 2 | HM | Article 2
Paragraph 2
No. 2 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 2 Paragraph 2 No. 4 | HM | Article 2
Paragraph 2
No. 4 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 28 Paragraph 1 | HM | Article 28
Paragraph 1 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 31 Paragraph 2-3 | HM | Article 31
Paragraph 2-3 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 33 | HM | Article 33 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 34 | HM | Article 34 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 4 | G | Article 4 | EN | EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 |
| GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (a) | HM | Article 2 (a) | EN | GBR Directive 2001/20/EC 04-Apr-2001 |
| GBR NIHR - National Institute for Health and Care Research 28-Jan-2025 - | G | - | EN | GBR NIHR - National Institute for Health and Care Research 28-Jan-2025 |
| GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 11 - 12 | HM | Article 11 - 12 | EN | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 2 clinical trial | HM | Article 2
clinical trial | EN | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 2 relevant ethics committee | HM | Article 2
relevant ethics committee | EN | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 3 (1) - (5) | HM | Article 3
(1) - (5) | EN | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 2 | HM | Schedule 1
Part 2 | EN | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| ICH ICH E6 Guideline - Annex 2 R3 Annex 2 Annex 2 Introduction | G | Annex 2
Introduction | EN | ICH ICH E6 Guideline - Annex 2 R3 Annex 2 |
| ICH ICH E6 Guideline R3 (2025) GLOSSARY - Clinical Trial | G | GLOSSARY - Clinical Trial | EN | ICH ICH E6 Guideline R3 (2025) |
| ICH ICH E7 Guideline 1993 - | G | - | EN | ICH ICH E7 Guideline 1993 |
| ICH ICH E9 Guideline - Addendum R1 20-Nov-2019 - | HM | - | EN | ICH ICH E9 Guideline - Addendum R1 20-Nov-2019 |
| USA 45 CFR Part 46 09-Apr-2025 § 46.102 (b) | G | § 46.102
(b) | EN | USA 45 CFR Part 46 09-Apr-2025 |
| USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018 - | G | - | EN | USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018 |
| WHO WHO - Guidance for best practices for clinical trials 2024 1.4 | G | 1.4 | EN | WHO WHO - Guidance for best practices for clinical trials 2024 |
| WHO WHO - Guidance for best practices for clinical trials 2024 2.4 | G | 2.4 | EN | WHO WHO - Guidance for best practices for clinical trials 2024 |
| WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - clinical trial | HM | Glossary - clinical trial | EN | WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 |
| WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - clinical trial Phases | HM | Glossary - clinical trial Phases | EN | WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 |
